3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-(methyl-4-pyridinylamino)- | 1263280-38-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-(methyl-4-pyridinylamino)-
• 英文别名: N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[methyl(pyridin-4-yl)amino]pyridine-3-carboxamide
• CAS: 1263280-38-1
• 化学式: C₂₂H₂₃N₅O
• 分子量: 373.5
• InChiKey: QMMTYHCSJITPGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• Heterocyclic Compound
  申请人：HASHIMOTO Kentaro

  公开号：US20110034469A1

  公开（公告）日：2011-02-10

  The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention shows a strong IAP antagonistic activity.

  本发明提供了一种由下式表示的化合物 其中，每个符号如说明书中所定义，或其盐。本发明的化合物表现出强烈的IAP拮抗活性。
• CYCLOPROPANAMINE COMPOUND AND USE THEREOF
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150266881A1

  公开（公告）日：2015-09-24

  The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R 1 , R 2 and R 3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R 1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R 2 and R 3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

  本发明提供一种具有赖氨酸特异性去甲基化酶1抑制作用的化合物，可用作预防或治疗精神分裂症、阿尔茨海默病、帕金森病或亨廷顿病等疾病的药物。本发明涉及一种由下式表示的化合物： 其中A是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；B是一个苯环，可选地具有进一步的取代基；R1、R2和R3分别是氢原子，或者是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；A和R1可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基；而R2和R3可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基，或其盐。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Okaniwa Masanori

  公开号：US20110237620A1

  公开（公告）日：2011-09-29

  A compound represented by formula (I) or a salt thereof, which has a potent Raf inhibitory activity. In formula (I), R 1 represents an optionally substituted C 1-6 alkyl, etc.; X represents —O— or —NR 2 — (wherein R 2 represents a hydrogen atom or a C 1-6 alkyl); Y represents a group represented by formula 2 ( 2 ii or 2 ii) (wherein ring A represents an optionally substituted benzene ring; Z represents a group represented by (1) —NR 3 CO—W 1 —, (2) —NR 3 CO—W 1 —O—, (3) —NR 3 CO—W 1 —O—W 2 —, (4) —NR 3 CO—W 1 —S—, (5) —NR 3 CO—W 1 —NR 4 —, (6) —NR 3 COO—, (7) —NR 3 COO—W 1 —, (8) —NR 3 CO—CO—, or (9) —NR 3 CONR 4 — (wherein R 3 and R 4 each represents a hydrogen atom, etc., and W 1 and W 2 each represents an optionally substituted C 1-6 alkylene, etc.); and R 5 represents an optionally substituted five- or six-membered ring group.

  化合物的化学式（I）或其盐，具有强大的Raf抑制活性。在化学式（I）中，R1代表一个可选择取代的C1-6烷基等；X代表—O—或—NR2—（其中R2代表氢原子或C1-6烷基）；Y代表由化学式2（2ii或2ii）表示的基团（其中环A代表可选择取代的苯环；Z代表由（1）—NR3CO—W1—，（2）—NR3CO—W1—O—，（3）—NR3CO—W1—O—W2—，（4）—NR3CO—W1—S—，（5）—NR3CO—W1—NR4—，（6）—NR3COO—，（7）—NR3COO—W1—，（8）—NR3CO—CO—，或（9）—NR3CONR4—（其中R3和R4各代表氢原子等，W1和W2各代表可选择取代的C1-6烷基等））；R5代表一个可选择取代的五元或六元环基团。
• [EN] BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS<br/>[FR] DÉRIVÉS DE BENZOTHIAZOLE CONVENANT COMME AGENTS ANTICANCÉREUX
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010064722A1

  公开（公告）日：2010-06-10

  Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

  提供了一个显示强烈Raf抑制活性的融合杂环衍生物。一个由式(I)表示的化合物，其中每个符号如本说明书中所定义，或其盐。